2022 World Conference on Lung Cancer (ePosters)-EP08.03-002. Local Ablative Therapy in Oligoprogressive NSCLC - Results from a Tertiary Cancer Center of India

Pdf Summary

This retrospective study evaluated the outcomes of oligoprogressive disease (OP) in non-small cell lung cancer (NSCLC) patients who received local ablative therapy (LAT). The study included 68 NSCLC patients with 84 OP lesions treated at a cancer center in India from 2018 to 2020.<br /><br />The results showed that 58 patients received LAT while 10 did not. Among the patients who received LAT, ongoing systemic therapy was continued in 42 patients. The median progression-free survival-1 (PFS-1) was 13.4 months, and the median follow-up was 13.8 months. Local control of treated OP sites was achieved in 88% of cases.<br /><br />The median progression-free survival-2 (PFS-2) in the LAT and non-LAT cohorts were 18.9 and 8.7 months, respectively. Progression after OP was seen in 46% of patients, with 15% experiencing progression at OP sites. The median overall survival (OS) was 50.6 months, and the OS after OP was 22.1 months.<br /><br />The study concluded that LAT after oligoprogression provides excellent local control and durable progression-free survival. LAT also allows for the continuation of ongoing effective systemic therapy in selected patients. The authors mentioned an ongoing prospective study (OligoChrome) that will further validate these findings and aid in the better selection of patients who can benefit the most from LAT.<br /><br />The study also provided additional information about the patient population, including their median age (52 years), histology (adenocarcinoma), driver mutations (EGFR and ALK positive), and the distribution of OP sites (brain, lung, bone). The types of ablative therapy used included stereotactic radiation therapy and hypofractionated radiation therapy.<br /><br />In summary, this study suggests that LAT can effectively control oligoprogressive disease in NSCLC patients, leading to improved survival outcomes. Further research is ongoing to better understand the role of LAT and identify patients who can benefit the most from this approach.

Asset Subtitle

Anil Tibdewal

Meta Tag

Speaker Anil Tibdewal

Topic Metastatic Non-small Cell Lung Cancer Oligometastatic Disease

Keywords

retrospective study

oligoprogressive disease

non-small cell lung cancer

local ablative therapy

NSCLC patients

outcomes

progression-free survival

local control

systemic therapy

patient population